CA2251292A1 - Composes a base de n-formyl hydroxylamine convenant comme inhibiteurs de l'enzyme ace et/ou de l'endopeptidase nep - Google Patents

Composes a base de n-formyl hydroxylamine convenant comme inhibiteurs de l'enzyme ace et/ou de l'endopeptidase nep Download PDF

Info

Publication number
CA2251292A1
CA2251292A1 CA002251292A CA2251292A CA2251292A1 CA 2251292 A1 CA2251292 A1 CA 2251292A1 CA 002251292 A CA002251292 A CA 002251292A CA 2251292 A CA2251292 A CA 2251292A CA 2251292 A1 CA2251292 A1 CA 2251292A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
aryl
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002251292A
Other languages
English (en)
Inventor
Jeffrey A. Robl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2251292A1 publication Critical patent/CA2251292A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des n-formyl hydroxylamines représentés par la structure (I). R et R?1¿ sont conformes à la description qui en est donnée dans la demande, et A est un dipeptide dérivé d'un acide aminé ou est un dipeptide mimique à conformation restreinte.
CA002251292A 1996-04-12 1997-04-07 Composes a base de n-formyl hydroxylamine convenant comme inhibiteurs de l'enzyme ace et/ou de l'endopeptidase nep Abandoned CA2251292A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1629596P 1996-04-12 1996-04-12
US60/016,295 1996-04-12

Publications (1)

Publication Number Publication Date
CA2251292A1 true CA2251292A1 (fr) 1997-10-23

Family

ID=21776392

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002251292A Abandoned CA2251292A1 (fr) 1996-04-12 1997-04-07 Composes a base de n-formyl hydroxylamine convenant comme inhibiteurs de l'enzyme ace et/ou de l'endopeptidase nep

Country Status (5)

Country Link
EP (1) EP0894003A4 (fr)
JP (1) JP2000511882A (fr)
AU (1) AU715451B2 (fr)
CA (1) CA2251292A1 (fr)
WO (1) WO1997038705A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
PL194240B1 (pl) 1998-02-07 2007-05-31 British Biotech Pharm Zastosowanie pochodnych N-formylohydroksyloaminy i amidowa pochodna N-formylohydroksyloaminy
US6774125B2 (en) 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
GB9827805D0 (en) 1998-12-16 1999-02-10 British Biotech Pharm Antibacterial agents
GB9907055D0 (en) * 1999-03-29 1999-05-19 British Biotech Pharm Antibacterial agents
ATE293600T1 (de) * 1999-08-10 2005-05-15 Vernalis Oxford Ltd Antibakterielle mittel
US6509330B2 (en) 2000-02-17 2003-01-21 Bristol-Myers Squibb Company Hydroxamic acid containing compounds useful as ACE inhibitors and/or NEP inhibotors
DE10020818A1 (de) 2000-04-28 2001-10-31 Degussa 2,6-Diamino-6-methyl-heptansäure und Derivate, Verfahren zu deren Herstellung und deren Verwendung
KR102055491B1 (ko) * 2015-05-22 2019-12-12 바이오테릭스, 인코포레이티드 단백질을 표적하는 화합물, 조성물, 방법, 및 그의 용도
WO2017201069A1 (fr) 2016-05-18 2017-11-23 Biotheryx, Inc. Dérivés d'oxoindoline utilisés comme modulateurs de la fonction protéique
US10882867B2 (en) * 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539150A (en) * 1983-06-29 1985-09-03 Mitsui Toatsu Chemicals, Inc. Benzothiazepine derivatives and their methods of preparation
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2679564A1 (fr) * 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
RU2124503C1 (ru) * 1992-05-18 1999-01-10 И.Р.Сквибб энд Санз, Инк. Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
ATE193706T1 (de) * 1993-11-16 2000-06-15 Novartis Ag Zyklische aminosäure-derivate mit ace und nep inhibierender aktivität
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors

Also Published As

Publication number Publication date
WO1997038705A1 (fr) 1997-10-23
EP0894003A1 (fr) 1999-02-03
EP0894003A4 (fr) 2000-10-04
JP2000511882A (ja) 2000-09-12
AU715451B2 (en) 2000-02-03
AU2609497A (en) 1997-11-07

Similar Documents

Publication Publication Date Title
CA2251292A1 (fr) Composes a base de n-formyl hydroxylamine convenant comme inhibiteurs de l'enzyme ace et/ou de l'endopeptidase nep
US4820729A (en) N-substituted-amido-amino acids
JPH06340691A (ja) ペプチド類
JPH0629228B2 (ja) ヒドロキシルアミン誘導体
SK63194A3 (en) Peptide derivatives
EP0037231A2 (fr) Dérivés acylés de l'acide octahydro-1H-indole-carboxylique-2
HU209413B (en) Method for producing 2-azabicyclo [3.1.0] hexane-3-carboxylic acid derivatives as well as their physiologically acceptable salts
NZ260675A (en) Phosphinyloxymethyl ketones containing 1-3 amino acids as enzyme inhibitors; medicaments
EP0253190B1 (fr) Analogues de la tuftsine partiellement rétro-inversés, leur méthode de préparation et compositions pharmaceutiques les contenant
JP2001511172A (ja) 特に神経興奮薬性アミノ酸に感受性をもつ中枢神経系受容体のエフェクターを構成する化合物、その製造およびその生物学的利用
CA1291478C (fr) Derives de pyridazodiazepine
EP0218688B1 (fr) Inhibiteurs de renine a substitution dihalo-statine
US4985407A (en) Dipeptide compounds, processes for their preparation and compositions containing them
GB2108118A (en) Pharmaceutical amides and preparation formulations and use thereof
CA2080227A1 (fr) Phosphonopeptides ayant une activite inhibitrice de la collagenase
CA2263732A1 (fr) Peptides et pseudodeptides azacycloalkylalcanoyle antithrombotiques
SU963463A3 (ru) Способ получени трипептидамидов
KR910001438B1 (ko) 광학적 활성 비시클릭 이미노-α-카복실산 에스테르 라세미체의 분할방법
EP0397427B1 (fr) Dérivés d'amide fluoré à activité inhibitrice d'élastase de leucocytes humains
US5145872A (en) Peptides with pharmaceutical activity
US6265381B1 (en) Orally-active elastase inhibitors
JPH0647599B2 (ja) ヘプタノイル―Ｇｌｕ―Ａｓｐ―Ａｌａ―アミノ酸系免疫賦活薬
US6777550B1 (en) N-formyl hydroxylamine containing compounds useful as ACE inhibitors and/or NEP inhibitors
Olma a-Hydroxymethylphenylglycine and a-Hydroxymethylphenylalanine: Synthesis, Resolution, and Absolute Configuration
KR890000769B1 (ko) 프롤린 유도체의 제법

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead